Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.5MCash on Hand
32.4mo Cash Runway
Follow BGMS by emailGet an email when BGMS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BGMS, unsubscribe in one click. Privacy
📣 What BGMS Says Is Next
fourth quarter of 2026 · “We are confident this combination will deliver long-term value for shareholders.” The Transaction is expected to close in the fourth quarter of 2026 subject to shareholder approval of both companies, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission to register the securities to be issued in connection with the Transaction, and the satisfaction of customary closing conditions.”
Company press release, Jun 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 revenue of $454,000 from fire safety products, up from $81,000, with a net loss of $0.4 million versus $1.0 million a year earlier. Cash was $3.5 million, expected to fund operations into Q2 2027, and the Future NRG business combination remains pending shareholder approval. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Financing Registers resale of 1,103,338 shares of common stock by selling stockholders, shares issued in a June 10, 2026 private placement at $0.72 per share for gross proceeds of $794,403. The company receives no proceeds from resales. Form 424B3 · SEC filing
Oct 23, 2026 ·
Financing Bio Green Med Solution registered for resale up to 1,103,338 shares of common stock held by selling stockholders, issued in a June 10, 2026 private placement at $0.72 per share for gross proceeds of $794,403. The company will not receive proceeds from these sales. Form S-3 · SEC filing
Oct 16, 2026 ·
Bio Green Med Solution declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock, payable November 1, 2026, to holders of record as of October 26, 2026. Form 8-K · SEC filing
Oct 9, 2026 ·
Deal BGMS seeks stockholder approval for a share exchange with Future NRG Sdn. Bhd. under a June 4, 2026 agreement with a $2,000,000,000 aggregate consideration value, issuing shares to Selling Shareholders who would own over 99.0% of Parent. Form 424B3 · SEC filing
Aug 14, 2026 ·
Earnings Reported Q2 2026 revenue of $336,000 from fire safety sales, net loss of $0.4 million versus $1.3 million a year earlier, and cash of $3.8 million expected to fund operations into Q1 2027. Also disclosed a Business Combination Agreement with Future NRG Sdn. Bhd. and a $794,403 share sale at $0.72 per share. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
BGMS holds $3.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $319,500/quarter from operations,
an estimated runway of 32.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:29 · Moderate
Cash runway 32 months
Going-concern doubt in the latest 10-Q +15The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or…10-Q, Nov 2026
Share count 6,622,794 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BGMS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BGMS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.